IDARUBICIN IN ADVANCED BREAST-CANCER - A PHASE-II STUDY
- 1 December 1986
- journal article
- research article
- Vol. 70 (12) , 1439-1440
Abstract
Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 .times. 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.This publication has 5 references indexed in Scilit:
- Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1985
- ACTIVITY AND DISTRIBUTION OF IV AND ORAL 4-DEMETHOXYDAUNORUBICIN IN MURINE EXPERIMENTAL-TUMORS1984
- PHASE-I AND CLINICAL-PHARMACOLOGY STUDIES OF INTRAVENOUS AND ORAL-ADMINISTRATION OF 4-DEMETHOXYDAUNORUBICIN IN PATIENTS WITH ADVANCED CANCER1983
- Antileukemic Activity of 4-Demethoxydaunorubicin in MiceTumori Journal, 1980
- QUANTITATIVE EXPERIMENTAL EVALUATION OF ADRIAMYCIN CARDIOTOXICITY IN THE MOUSE1979